自体外周血干细胞移植治疗肝硬化患者的长期结局
该回顾性队列分析比较了2006年至2016年间中国282例接受自体外周血干细胞移植与286例接受标准药物治疗的失代偿期肝硬化患者,经倾向性评分匹配后,干细胞移植组生存时间显著更高,5年生存率分别为71.2%和52.1%,两组肝细胞癌总体发生率无显著差异(21.1% vs 20.4%,P=.999)。
要点
- 自体外周血干细胞移植组长期生存时间显著高于标准药物治疗组(P=.001)。
- 匹配后5年生存率干细胞移植组为71.2%,标准药物治疗组为52.1%。
- 两组肝细胞癌总体发生率无显著差异(21.1% vs 20.4%,P=.999)。
核心结论
- 在失代偿期肝硬化患者的长期分析中,与对照组相比,自体外周血干细胞移植显著改善了长期生存。
- 外周血干细胞移植似乎未增加肝细胞癌风险。
研究设计与样本
- 回顾性分析两个队列:接受自体外周血干细胞移植的失代偿期肝硬化患者282例和接受标准药物治疗的患者286例,纳入时间为2006年1月1日至2016年12月31日,地点为中国。
- 随访至死亡或肝移植,采用倾向性评分匹配调整两组差异,使用Cox比例风险回归确定预后因素。
主要发现
- 倾向性评分匹配后,外周血干细胞移植组生存时间显著高于标准药物治疗组(P=.001)。
- 调整后5年生存率外周血干细胞移植组为71.2%,标准药物治疗组为52.1%。
- 肝细胞癌总体发生率在外周血干细胞移植组与标准药物治疗组之间无显著差异(21.1% vs 20.4%;P=.999)。
- 与标准药物治疗组相比,外周血干细胞移植后1年、2年、3年和5年时观察到肝功能显著改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Peripheral blood stem cells (PBSCs) mobilized with colony-stimulating factor can promote liver regeneration and increase liver function in patients with liver diseases. However, the long-term effects of stem cell treatments on survival and risk of hepatocellular carcinoma (HCC) in patients with cirrhosis have not been determined. We investigated the long-term effects of autologous stem cell transplantation and risk of HCC in patients with cirrhosis. METHODS: We performed a retrospective analysis of 2 cohorts of patients with decompensated cirrhosis who received transplantations of autologous PBSCs (n = 282) or standard medical treatment (SMT, n = 286) in China from January 1, 2006, through December 31, 2016. Patients were followed up until death or liver transplantation. Mortality data were obtained by case records and confirmed by telephone calls. Survival time was calculated and HCC was confirmed by computed tomography or ultrasound. We used propensity score matching to adjust the differences between the 2 groups. Survival and incidence of HCC were analyzed and Cox proportional hazard regression was used to determine the prognostic factors. RESULTS: After propensity score matching, time of survival was significantly higher in the PBSC group than the SMT group (P = .001). The adjusted rate of 5-year survival was 71.2% in the PBSC group and 52.1% in the SMT group. The overall incidence of HCC did not differ significantly between the PBSC and SMT groups (21.1% vs 20.4%; P = .999). Significant improvement of liver functions was observed at 1 year, 2 years, 3 years, and 5 years after PBSC transplantation compared with the SMT group. CONCLUSIONS: In a long-term analysis of patients with decompensated cirrhosis, autologous transplants of PBSCs significantly improved long-term survival compared with a control group. PBSC transplant did not appear to increase the risk of HCC.
引用
- Guo C, Guo G, Zhou X, et al. Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018. PMID: 30613001. doi:10.1016/j.cgh.2018.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。